Get the Stockscreener App
7.87
1.03%
0.08
Zevra Therapeutics Inc stock is traded at $7.87, with a volume of 363.46K.
It is up +1.03% in the last 24 hours and up +14.89% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.79
Open:
$7.82
24h Volume:
363.46K
Relative Volume:
0.81
Market Cap:
$437.43M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-6.1008
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-1.62%
1M Performance:
+14.89%
6M Performance:
-12.56%
1Y Performance:
+56.46%
1-Day Range:
$7.82
$8.08
1-Week Range:
$7.2626
$8.09
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.87 | 437.43M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by MetLife Investment Management LLC - Defense World
Wells Fargo & Company MN Has $248,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics at Citizens JMP: Strategic Focus on MyPlayfa and Soliprolol - Investing.com
(ZVRA) Trading Advice - news.stocktradersdaily.com
Alucio™ Adds Zevra Therapeutics to its Expanding Base of Life Science Customers - PR Newswire
Zevra Therapeutics Announces Details for Q1 2025 Financial Resul - GuruFocus
Zevra Therapeutics, Inc. to Report First Quarter 2025 Corporate and Financial Results on May 13, 2025 - Nasdaq
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call - GlobeNewswire
Zevra Therapeutics Sets Q1 2025 Earnings Date: Key Details for Rare Disease Portfolio Update - Stock Titan
Zevra Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $153,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by JPMorgan Chase & Co. - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Could Be Less Than A Year Away From Profitability - simplywall.st
Are Zevra Therapeutics Inc (ZVRA) shares a good deal now? - uspostnews.com
Zevra Therapeutics to Participate in the Citizens Life Science Conference - The Manila Times
Rare Disease Leader Zevra Therapeutics Reveals Growth Strategy at Citizens Conference - Stock Titan
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Geode Capital Management LLC Has $9.91 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Investment Analysis and Advice - news.stocktradersdaily.com
Zevra calls for stockholder support against board influence bid - Investing.com
Zevra Therapeutics (ZVRA) Prepares for 2025 Annual Meeting, Advocates for Board Stability | ZVRA Stock News - GuruFocus
Zevra calls for stockholder support against board influence bid By Investing.com - Investing.com India
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders | ZVRA Stock News - GuruFocus
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - The Manila Times
Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns - Nasdaq
ZVRAZevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Form DEFC14A ZEVRA THERAPEUTICS, INC. Filed by: ZEVRA THERAPEUTICS, INC. - StreetInsider
ZVRA Stock Sees Surge of Approximately 8.99% in Last Five Days - knoxdaily.com
Zevra Therapeutics (ZVRA) Reveals Key Insights into Niemann-Pick Type C Treatment | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism | ZVRA Stock News - GuruFocus
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism - GlobeNewswire
Breakthrough Study Uncovers MIPLYFFA's Mechanism for Treating Fatal Genetic Disease NPC - Stock Titan
Vanguard Group Inc. Grows Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Corebridge Financial Inc. Buys 3,801 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Raymond James Financial Inc. Purchases Shares of 26,916 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Institutional investors may overlook Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) recent US$44m market cap drop as long-term gains remain positive - simplywall.st
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher - MarketScreener
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves - marketscreener.com
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - citybiz
$150M FDA Voucher Sale Transforms Zevra's Financial Position: Rare Disease Success Story - Stock Titan
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline - MSN
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Brokerages - Defense World
(ZVRA) Technical Data - news.stocktradersdaily.com
Zevra Therapeutics: Mixed Feelings On Miplyffa Approval (NASDAQ:ZVRA) - Seeking Alpha
Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra therapeutics director Corey Watton buys $2,351 in stock By Investing.com - Investing.com Australia
Zevra therapeutics director Corey Watton buys $2,351 in stock - Investing.com
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor - MarketScreener
Zevra Therapeutics Files Preliminary Proxy - The Manila Times
Proxy Fight Erupts at Zevra: Former CEO Challenges $150M Cash-Rich Biotech - Stock Titan
Charles Schwab Investment Management Inc. Buys 28,148 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bode John B | Director |
Mar 19 '25 |
Buy |
7.96 |
10,000 |
79,624 |
40,000 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller |
Feb 13 '25 |
Sale |
7.86 |
3,000 |
23,588 |
16,341 |
| Schafer Joshua | CCO & EVP, Bus. Development |
Feb 13 '25 |
Sale |
7.86 |
10,500 |
82,527 |
29,486 |
| Clifton R. LaDuane | CFO & Treasurer |
Feb 13 '25 |
Sale |
7.86 |
11,000 |
86,471 |
51,361 |
| McFarlane Neil F. | President and CEO |
Feb 13 '25 |
Sale |
7.86 |
61,273 |
481,428 |
222,060 |
| McFarlane Neil F. | President and CEO |
Feb 14 '25 |
Sale |
8.05 |
30,544 |
245,962 |
191,516 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):